International Journal of Clinical Oncology

, Volume 11, Issue 2, pp 82–89

Current status and perspective of antiangiogenic therapy for cancer: hepatocellular carcinoma


DOI: 10.1007/s10147-006-0566-5

Cite this article as:
Tanaka, S. & Arii, S. Int J Clin Oncol (2006) 11: 82. doi:10.1007/s10147-006-0566-5


Hepatocellular carcinoma (HCC) is well known as a typical angiogenic tumor, especially in the moderately to poorly differentiated type. Such clinicopathological characteristics are not only useful for imaging diagnosis but are also applicable to the treatment of HCC. In addition, recent molecular studies have revealed that angiogenesis is closely related to hepatocarcinogenesis. In this review, the molecular mechanism of HCC angiogenesis and the antiangiogenic prevention of HCC are reviewed to introduce the latest trends in antiangiogenic treatment of cancers, including HCC.

Key words

Hepatocellular carcinoma Angiogenesis Angiogenic switch VEGF Angiopoietin Molecularly targeted antiangiogenic therapy 

Copyright information

© The Japan Society of Clinical Oncology 2006

Authors and Affiliations

  1. 1.Department of Hepato-Biliary-Pancreatic SurgeryTokyo Medical and Dental University, Graduate School of MedicineTokyoJapan

Personalised recommendations